Showing results (101-110 of 113) with videos related to
Sort By:
Pageof 12
Cancer Chemotherapy and Pharmacology|June 1, 2006
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanomaMonica M Mita, Eric K Rowinsky, Leonardo Forero, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2008
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignanciesMonica M Mita, Alain C Mita, Quincy S Chu, et al.The New England Journal of Medicine|February 10, 2006
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neckJames A Bonner, Paul M Harari, Jordi Giralt, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignanciesLillian L Siu, Eric K Rowinsky, Lisa A Hammond, et al.International Journal of Radiation Oncology, Biology, Physics|February 18, 2004
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibodyKenneth A Foon, Xiao-Dong Yang, Louis M Weiner, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2006
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal functionAlain C Mita, Christopher J Sweeney, Sharyn D Baker, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2010
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2Jennifer L Spratlin, Roger B Cohen, Matthew Eadens, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2003
Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative studyAnthony W Tolcher, Leonel Ochoa, Lisa A Hammond, et al.Haematologica|November 9, 2014
In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agentFanny Angelot-Delettre, Anne Roggy, Arthur E Frankel, et al.The Lancet. Oncology|March 28, 2024
LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 studyBenjamin L Musher, Eric K Rowinsky, Brandon G Smaglo, et al.Pageof 12